Shots: 

• Smith & Nephew acquires Osiris Therapeutics- in all stock transaction for $19/share at a premium of 37% making the total deal value $660M. The transaction is expected to close in Q2’19 with the joining of 360 employees to Smith & Nephew
• The focus of an acquisition is to expand Smith & Nephew’s regenerative drugs portfolio and to enhance its wound management business with the usage of Osiris’ lead candidates Grafix & Stravix
• Osiris’ Grafix & Stravix is a cryopreserved placental membrane & tissue used to heal wounds with exposed bone and tendon and to support tissue repair respectively

Ref: Smith & Nephew | Image: Morgan-Keller Construction